二甲双胍治疗NASH的临床评价  

A clinical assessment about metformin on NASH

作　　者：郝美君[1] 张祯祯[1] 程丽英[1] 黄爱龙[1] 

机构地区：[1]重庆医科大学肝病研究所感染性疾病分子生物学教育部重点实验室,重庆400016

出　　处：《中国医药导报》2008年第25期50-51,共2页China Medical Herald

摘　　要：目的:评价二甲双胍治疗NASH的临床疗效。方法:入选病人随机分为对照和治疗组,分别给予保肝、饮食运动综合治疗和在此基础上的二甲双胍治疗。结果:BMI、FI、ALT、AST、GGT等均有明显改善。结论:二甲双胍治疗NASH的临床疗效是肯定的。Objective：The present randomized, double blind controlled study was designed to compare the clinical and metabolic effects of two treatment models for NASH and reveal an influence of mefformin on the NASH. Methods：56 patients with NASH were divided into mefformin group and control group. The control group received glycyrrhizin and lifestyle modification. The mefformin group received mefformin and glyeyrrhizin and lifestyle modification. All investigations： AST, BMI, FI, ALT, GGT, TC, TG, HDL-C, FBS were performed. Results ： AST, BMI, FI, ALT, GGT, HDL-C were significantly improved. Conclusion：Mefformin＇s effects on NASH are granted.

关 键 词：二甲双胍 NASH 

分 类 号：R587.1[医药卫生—内分泌]